Extra chemo after stomach cancer surgery: compare two drug plans
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent before any study procedures
- Your diagnosis must be stomach or stomach–esophagus junction adenocarcinoma confirmed by biopsy
- You must have had surgery to remove the tumor with wide lymph node removal, with no remaining tumor (R0) on post-op staging
- Your post-operative cancer stage must be IIIB or IV, and not include distant metastasis (M1)
- You must be able to start randomization within 6 weeks after surgery
- You need to be between 20 and 75 years old and well enough for oral medicines and standard chemo
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
Hear when a new Gastric Cancer, Adjuvant Chemotherapy, XO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.